Viatris Inc — Director's Dealing 2020

Nov 18, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Viatris Inc (VTRS)
CIK: 0001792044
Period of Report: 2020-11-16

Reporting Person: DIMICK NEIL F (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-11-16	Common Stock	A	51263	—	Acquired	51263	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-11-16	Non-Employee Director Stock Option - Right to Buy	$45.72	A	2974	Acquired	2024-04-11	Common Stock (2974)	Direct
2020-11-16	Non-Employee Director Stock Option - Right to Buy	$50.66	A	2603	Acquired	2025-11-17	Common Stock (2603)	Direct
2020-11-16	Non-Employee Director Stock Option - Right to Buy	$46.27	A	2788	Acquired	2026-02-17	Common Stock (2788)	Direct
2020-11-16	Non-Employee Director Stock Option - Right to Buy	$45.18	A	2928	Acquired	2027-03-03	Common Stock (2928)	Direct
2020-11-16	Non-Employee Director Stock Option - Right to Buy	$40.97	A	2984	Acquired	2028-03-02	Common Stock (2984)	Direct
2020-11-16	Non-Employee Director Stock Option - Right to Buy	$27.45	A	4352	Acquired	2029-03-01	Common Stock (4352)	Direct
2020-11-16	Non-Employee Director Stock Option - Right to Buy	$17.48	A	6151	Acquired	2030-03-02	Common Stock (6151)	Direct
2020-11-16	Restricted Stock Units	$0.00	A	9440	Acquired		Common Stock (9440)	Direct

Footnotes

F1: On November 16, 2020, Mylan N.V. ("Mylan") completed the transaction pursuant to which Mylan combined with Pfizer Inc.'s ("Pfizer") Upjohn business (the "Upjohn Business") in a Reverse Morris Trust transaction (the "Combination") and Upjohn Inc. ("Upjohn") became the parent entity of the combined Upjohn Business and Mylan business and was renamed "Viatris Inc." ("Viatris"). Pursuant to the terms of the Business Combination Agreement (as amended), dated July 29, 2019, by and among Mylan, Pfizer, Upjohn and certain other affiliated entities, Upjohn and Mylan effected the Combination through a series of transactions, including that each holder of Mylan ordinary shares received one share of Viatris common stock for each Mylan ordinary share held by such holder (subject to any required withholding tax).

F2: Represents shares of Viatris common stock acquired in connection with the Combination on a one-for-one basis in exchange for ordinary shares of Mylan. On the effective date of the Combination, the closing price of a Mylan ordinary share was $15.85 per share.

F3: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F4: These options vested on April 11, 2015.

F5: These options vested on May 1, 2016.

F6: These options vested on February 17, 2017.

F7: These options vested on March 3, 2018.

F8: These options vested on March 2, 2019.

F9: These options vested on March 2, 2020.

F10: These options will vest on March 2, 2021

F11: Received in exchange for, and having substantially the same terms as, restricted stock units ("RSUs") of Mylan in connection with the Combination.

F12: Each RSU represents the right to receive one share of common stock of Viatris. The RSUs will vest on March 2, 2021.